

Acute NIV on the ward: Case studies and trouble shooting.

Karen Brewin – Lead Respiratory Physiotherapist
Northumbria Healthcare NHS FT

Dr Nicholas Lane – Respiratory Consultant
The Newcastle Upon Tyne Hospitals NHS FT

Non-Invasive Ventilation



Indications for NIV

- Acute hypercapnic respiratory failure (respiratory acidaemia):
 - pH < 7.35
 - PaCO₂ > 6.5 kPa
- ECOPD
- NMD
 - Even if RR >20 and VC <1L and normal PaCO₂ with respiratory illness
- OHS +/- OSA
- Chest wall deformity

Contraindications to NIV

- Absolute

- Facial deformity or burns
- Fixed upper airway obstruction
- Undrained pneumothorax

- Relative

- pH <7.15 (or pH <7.25 with an additional adverse feature)
- Factors affecting compliance of wearing the face mask
- Unprotected airway / GCS <8
- Copious respiratory secretions

What about asthma or pneumonia?

NIV Not indicated

Asthma/Pneumonia

Refer to ICU for consideration IMV if
increasing respiratory rate/distress

or

pH < 7.35 and pCO₂ > 6.5

- Asthma
 - If hypercapnic = near fatal asthma
- Pneumonia
 - Perhaps...
 - If it's complicating another condition known to be responsive to NIV.

Criteria for considering Intubation

- Progressive/persistent respiratory acidaemia
- Unable to maintain SpO₂
- GCS <8
- Agitation limiting adherence
- Life-threatening arrhythmia/haemodynamic instability
- Cardiorespiratory arrest
- Contraindications to NIV

NIV Set-Up

- Equipment:

- Ventilator, filter, circuit, mask
- Oxygen supply (SpO₂ 88-92%)
- Nebuliser T-piece

- Settings:

- Spontaneous/timed (S/T)
- IPAP, EPAP, Back up rate, I-time

- Good practice:

- NIV as much as possible in first 24 hours
- Wean over 48 to 72 hours
- Escalation and cardiopulmonary resuscitation decisions prior to starting acute ventilation



Monitoring on NIV

- SpO₂, RR, HR, BP
 - Hourly until stable and pH normal
- Temp
 - 4 hourly
- ABG's
 - 1 to 2 hours, and 4 to 6 hours
- Consultant review
 - Within 14 hours
- Nursing/AHP staffing
 - 1:2 in the acute phase (generally first 24-48hrs)



Case Study 1

- 71 female
- SOB, chest pain, wheeze and cough
- Arrived in ED at 21:08
- PMH COPD, rescue pack amoxicillin and prednisolone
- Ex-smoker, lives with sister, can get washed and dressed
- Triage P2 at 21:21
- Medical assessment 22:00
- Diagnosis IECOPD

Arterial blood gases

	23:31
pH	7.34
PaCO ₂	8.1
PaO ₂	8.0
HCO ₃ ⁻	32.9
BE	7.1
SaO ₂	88%
FiO ₂	0.28

Arterial blood gases

	23:31	02:32
pH	7.34	7.29
PaCO ₂	8.1	9.3
PaO ₂	8.0	8.5
HCO ₃ ⁻	32.9	33.2
BE	7.1	6.6
SaO ₂	88%	91%
FiO ₂	0.28	0.28

Arterial blood gases

	23:31	02:32	04:42
pH	7.34	7.29	7.23
PaCO ₂	8.1	9.3	10.4
PaO ₂	8.0	8.5	7.9
HCO ₃ ⁻	32.9	33.2	32.7
BE	7.1	6.6	5.1
SaO ₂	88%	91%	86%
FiO ₂	0.28	0.28	0.28


NIV commenced at 04:45.

Trouble shooting

- Failure to recognise need for NIV
- Door to mask time 7 hours 37 minutes

This wall chart should **always** be used in conjunction with the full NIV guideline. Decompensated type 2 respiratory failure is a medical emergency. NIV dramatically improves survival. Delayed NIV initiation is associated with increased mortality. NIV 'buys time': DO NOT neglect standard medical therapy.

Acute Non-Invasive Ventilation Guideline Wall Chart



Indications: **PRIOR TO Specialist Approval:**

pH < 7.35 and PaCO₂ > 6.5 due to:

- Exacerbation of COPD
- Obesity hypoventilation syndrome (OHS)
- Chest wall deformity
- Neuromuscular disease
- Left ventricular failure (CPAP first line)

Indications: **ONLY with Specialist Approval:**

pH < 7.35 and PaCO₂ > 6.5 due to other conditions including:

- CF / bronchiectasis
- Immunocompromised patient
- Chronic asthma (airways remodeling)

Compensated Hypercapnia (pH ≥ 7.35) with / due to:

- Progressive fatigue / drowsiness
- Neuromuscular disease
- Chest wall deformity

Absolute Contra-indications:

- Facial deformity preventing mask seal
- Facial Burns
- Fixed upper airway obstruction
- Undrained pneumothorax (urgent chest drain)

NB low GCS presumed due to hypercapnia: NIV if otherwise appropriate and improving within 2 hours. Consider critical care review.

Consider Intubation:

- Clinical deterioration despite optimisation of NIV, including:
 - Progressive respiratory acidaemia (pH < 7.25 and falling, rising PaCO₂)
 - Persistent severe acidaemia (especially pH < 7.15)
 - PaO₂ < 6 kPa despite FiO₂ 100% on NIV
 - GCS < 8
 - Marked agitation limiting adherence
- Life-threatening arrhythmia or haemodynamic instability
- Cardio-respiratory arrest / Peri-arrest
- Contra-indication to NIV

This wall chart should **always** be used in conjunction with the full NIV guideline. Decompensated type 2 respiratory failure is a medical emergency. NIV dramatically improves survival. Delayed NIV initiation is associated with increased mortality. NIV 'buys time': DO NOT neglect standard medical therapy.

Acute Non-Invasive Ventilation Guideline Wall Chart



pH < 7.25 & PaCO₂ > 6.5
OR pH < 7.35, PaCO₂ > 6.5
& rapid deterioration

Clinically exclude pneumothorax then initiate NIV immediately (contact physio)

Arrange urgent physiotherapy
Control oxygen saturation
Obtain urgent CXR

All patients should be established on NIV by 120 mins. (Breaches subject to root cause analysis)

Repeat ABG at 1 and 4 hours in all patients. RR, HR, BP temp hourly for at least 4 hours until clinically stable and pH normal. Consider critical care therapy

pH 7.25-7.34 & PaCO₂ > 6.5

Obtain urgent CXR
Set Oxygen target
92%
Initiate medical therapy

Repeat ABG at 60 mins
Repeat ABG at 120 mins
Repeat ABG at 180 mins

Reassess: a) NIV settings and circuit; b) clinical management. Consider critical care management.

"They are only a little bit acidaemic"

Indications: **PRIOR TO Specialist Approval:**

pH < 7.35 and PaCO₂ > 6.5 due to:

- Exacerbation of COPD
- Obesity hypoventilation syndrome (OHS)
- Chest wall deformity
- Neuromuscular disease
- Left ventricular failure (CPAP first line)

Indications: **Specialist Approval:**

pH < 7.35 and PaCO₂ > 6.5 conditions include:

- CF / bronchiectasis
- Immunocompromised patients
- Chronic asthma (airways remodeling)

Compensated Hypercapnia (pH ≥ 7.35) with / due to:

- Progressive fatigue / drowsiness
- Neuromuscular disease
- Chest wall deformity

Absolute Contraindications:

- Facial deformity

NB low GCS presumed due to hypercapnia: NIV if otherwise appropriate and improving within 2 hours. Consider critical care review.

Relative Contraindications:

Worsening clinical deterioration despite optimisation of medical therapy, including:

- Progressive respiratory acidaemia (pH < 7.25 and falling, rising PaCO₂)
- Persistent severe acidaemia (especially pH < 7.15)
- PaO₂ < 6 kPa despite FiO₂ 100% on NIV
- GCS < 8
- Marked agitation limiting adherence

• Life-threatening arrhythmia or haemodynamic instability


• Cardio-respiratory arrest / Peri-arrest

• Contra-indication to NIV

Problems with recognising the need for NIV

- Under recognition is probably the single biggest barrier to improvement
- Poor quality services
 - NCEPOD report - only 27.5% of patients have 'good quality' NIV
- Variation between institutions and clinicians
 - Institution attended the strongest predictor of whether NIV is received
 - Of the indices used by clinicians to decide NIV treatment only one associated with inpatient survival

Prognostic pessimism



- Patients do better than we think they might
- Anything above the blue line is overly pessimistic on the clinician predicted outcome
- 4 fold difference in the lowest group!
 - Predicted survival 10%
 - Actual survival 40%

Clinical tools / prognostic scores

- Can help challenge pessimism and objectify outcomes.

NIVO score	Points
Consolidation	1
GCS <15	1
AF	1
pH <7.25	1
Time to Acidaemia >12 hours	2
eMRC5a	2
eMRC5b	3
	/9

Risk Group (NIVO scores)	N=	Inpatient mortality	
		N=	%
Low Risk 0-2	279	14	5.0%
Medium Risk 3-4	268	45	16.8%
High Risk 5-6	151	63	41.7%
Very High Risk 7-9	35	25	71.4%

NIVO illustration

Patient 1

- 82 seen in ED, drowsy.
- Pneumonia.
- COPD, Diabetes, CVA.
- Struggles round the block walking dog.
- pH 7.14, CO₂ 9.1

Patient 2

- 58 seen on respiratory ward day 2.
- Uses mobility scooter out of house, otherwise independent.
- COPD, AF on Rivaroxaban.
- Nil else of note.
- pH 7.31, CO₂ 9.1

NIVO Illustration

Patient 1

- 82 seen in ED, **drowsy**.
- **Pneumonia**.
- COPD, Diabetes, CVA.
- Struggles round the block walking dog.
- **pH 7.14**, CO₂ 9.1
- **NIVO SCORE = 3**

Patient 2

- 58 seen on respiratory ward **day 2**.
- **Uses mobility scooter out of house, otherwise independent**.
- COPD, **AF** on Rivaroxaban.
- Nil else of note.
- pH 7.31, CO₂ 9.1
- **NIVO SCORE = 5**

NIVO

Patient

- 82 seen
- Pneumonia
- COPD,
- Struggled to walk, dog.
- pH 7.1

■ NIVO SCORE = 3

■ NIVO SCORE = 5

Risk Group (NIVO scores)	N=	Inpatient mortality	
		N=	%
Low Risk 0-2	279	14	5.0%
Medium Risk 3-4	268	45	16.8%
High Risk 5-6	151	63	41.7%
Very High Risk 7-9	35	25	71.4%

laboratory ward day 2.
 later out of house,
 independent.
 roxaban.

Case Study 2

- 71 Female
- SOB and productive cough
- PMH COPD
- Ex-smoker, lives with son, indep mobile
- Covid +ve, triple vaccinated, sinus rhythm, MRCD 4
- TEP Ward based ceiling of care
- Diagnosis ECOPD
- ABG pH 7.30, PaCO₂ 9.8, PaO₂ 9.5, HCO₃⁻ 35.9, BE 9.5, SaO₂ 95%

- Obs
 - BP 120/66, HR 68, Temp 35.8, RR 20, and SpO₂ 92% on 28% oxygen
- NIV: IPAP 26, EPAP 5, Rate 18, I-time 1.1, FiO₂ 25%
- 15 mins on NIV: BP 66/42
- IPAP ↓20, Dr: 500ml NaCl 0.9%

	Pre-NIV	1 hour of NIV
pH	7.30	7.29
PaCO ₂	9.8	10.1
PaO ₂	9.5	8.0
HCO ₃ ⁻	35.9	35.6
BE	9.5	8.8
SaO ₂	95%	90%
NIV / FiO ₂	0.28	20/5 + 18 I-time 1.1 FiO ₂ 0.25 BP 105/71

	Pre-NIV	1 hour of NIV	Changes made
pH	7.30	7.29	IPAP ↑ 26
PaCO ₂	9.8	10.1	Rate ↑ 20
PaO ₂	9.5	8.0	I-time ↓ 1.0
HCO ₃ ⁻	35.9	35.6	
BE	9.5	8.8	
SaO ₂	95%	90%	
NIV / FiO ₂	0.28	20/5 + 18 I-time 1.1 FiO ₂ 0.25 BP 105/71	

	Pre-NIV	1 hour of NIV	Changes made	1 hour later
pH	7.30	7.29	IPAP ↑ 26	7.33
PaCO ₂	9.8	10.1	Rate ↑ 20	8.8
PaO ₂	9.5	8.0	I-time ↓ 1.0	9.4
HCO ₃ ⁻	35.9	35.6		35.2
BE	9.5	8.8		8.6
SaO ₂	95%	90%		96%
NIV / FiO ₂	0.28	20/5 + 18 I-time 1.1 FiO ₂ 0.25 BP 105/71		26/5 + 20 I-time 1.0 FiO ₂ 0.25

	Pre-NIV	1 hour of NIV	Changes made	1 hour later	Changes made
pH	7.30	7.29	IPAP ↑ 26	7.33	FiO ₂ ↓ 0.22
PaCO ₂	9.8	10.1	Rate ↑ 20	8.8	
PaO ₂	9.5	8.0	I-time ↓ 1.0	9.4	
HCO ₃ ⁻	35.9	35.6		35.2	
BE	9.5	8.8		8.6	
SaO ₂	95%	90%		96%	
NIV / FiO ₂	0.28	20/5 + 18 I-time 1.1 FiO ₂ 0.25 BP 105/71		26/5 + 20 I-time 1.0 FiO ₂ 0.25	

	4 hours later
pH	7.32
PaCO ₂	9.0
PaO ₂	8.1
HCO ₃ ⁻	35.4
BE	8.9
SaO ₂	91%
NIV / FiO ₂	26/5 + 20 I-time 1.0 FiO ₂ 0.22

	4 hours later	Changes made
pH	7.32	IPAP ↑ 30
PaCO ₂	9.0	
PaO ₂	8.1	
HCO ₃ ⁻	35.4	
BE	8.9	
SaO ₂	91%	
NIV / FiO ₂	26/5 + 20 I-time 1.0 FiO ₂ 0.22	

	4 hours later	Changes made	ABG 1 hour later
pH	7.32	IPAP ↑ 30	7.35
PaCO ₂	9.0		8.3
PaO ₂	8.1		8.4
HCO ₃ ⁻	35.4		34.2
BE	8.9		8.6
SaO ₂	91%		92%
NIV / FiO ₂	26/5 + 20 I-time 1.0 FiO ₂ 0.22		30/5 + 20 I-time 1.0 FiO ₂ 0.22

	4 hours later	Changes made	ABG 1 hour later	Changes made
pH	7.32	IPAP ↑ 30	7.35	I-time ↓ 0.75
PaCO ₂	9.0		8.3	I:E ratio 1:3
PaO ₂	8.1		8.4	
HCO ₃ ⁻	35.4		34.2	
BE	8.9		8.6	
SaO ₂	91%		92%	
NIV / FiO ₂	26/5 + 20 I-time 1.0 FiO ₂ 0.22		30/5 + 20 I-time 1.0 FiO ₂ 0.22	

	4 hours later	Changes made	ABG 1 hour later	Changes made	Repeat ABG
pH	7.32	IPAP ↑ 30	7.35	I-time ↓ 0.75	7.41
PaCO ₂	9.0		8.3	I:E ratio 1:3	6.8
PaO ₂	8.1		8.4		8.0
HCO ₃ ⁻	35.4		34.2		32.3
BE	8.9		8.6		7.7
SaO ₂	91%		92%		92%
NIV / FiO ₂	26/5 + 20 I-time 1.0 FiO ₂ 0.22		30/5 + 20 I-time 1.0 FiO ₂ 0.22		30/5 + 20 I-time 0.75 FiO ₂ 0.22

Troubleshooting

COPD settings

IPAP	Start 15 cmH ₂ O; aim 20-30 cmH ₂ O
EPAP	Start 3 cmH ₂ O
Back up rate	16 to 20
I-time	Set to achieve I:E ratio of 1:2

- Hypotension
- Increased PaCO₂
- Target SpO₂ 88-92%

Case Study 3

- 76 year old female
- Admitted with dry cough, shortness of breath and confusion
- PMH: COPD, OSA, obesity
- SH: Ex-smoker, lives alone, mobile with stick, indep ADL's
- Diagnosis: ECOPD, T2RF
- Treatment: Abx, pred, nebs, NIV

	Pre-NIV	NIV settings
pH	7.32	IPAP 26
PaCO ₂	9.6	EPAP 8
PaO ₂	11.7	Rate 18
HCO ₃ ⁻	37.1	I-time 1.65
BE	11.0	FiO ₂ 0.28
SaO ₂	98%	
NIV / FiO ₂	0.35	

	Pre-NIV	NIV settings	1 hour of NIV
pH	7.32	IPAP 26	7.31
PaCO ₂	9.6	EPAP 8	10.3
PaO ₂	11.7	Rate 18	7.4
HCO ₃ ⁻	37.1	I-time 1.65	38.8
BE	11.0	FiO ₂ 0.28	11.2
SaO ₂	98%		90%
NIV / FiO ₂	0.35		26/8 + 18 I-time 1.65 FiO ₂ 0.65

	Pre-NIV	NIV settings	1 hour of NIV	Changes made
pH	7.32	IPAP 26	7.31	IPAP ↑ 28
PaCO ₂	9.6	EPAP 8	10.3	
PaO ₂	11.7	Rate 18	7.4	
HCO ₃ ⁻	37.1	I-time 1.65	38.8	
BE	11.0	FiO ₂ 0.28	11.2	
SaO ₂	98%		90%	
NIV / FiO ₂	0.35		26/8 + 18 I-time 1.65 FiO ₂ 0.65	

	Repeat ABG
pH	7.31
PaCO ₂	10.2
PaO ₂	7.6
HCO ₃ ⁻	37.9
BE	12.6
SaO ₂	91%
NIV	28/8 + 18 I-time 1.65 FiO ₂ 0.28

	Repeat ABG	Changes made
pH	7.31	IPAP ↑ 30
PaCO ₂	10.2	
PaO ₂	7.6	
HCO ₃ ⁻	37.9	
BE	12.6	
SaO ₂	91%	
NIV	28/8 + 18 I-time 1.65 FiO ₂ 0.28	

	Repeat ABG	Changes made	Repeat ABG
pH	7.31	IPAP ↑ 30	7.33
PaCO ₂	10.2		9.8
PaO ₂	7.6		7.3
HCO ₃ ⁻	37.9		38.0
BE	12.6		12.4
SaO ₂	91%		88%
NIV	28/8 + 18 I-time 1.65 FiO ₂ 0.28		30/8 + 18 I-time 1.65 FiO ₂ 0.28

	Repeat ABG	Changes made	Repeat ABG	Changes made
pH	7.31	IPAP ↑ 30	7.33	EPAP ↑ 10
PaCO ₂	10.2		9.8	
PaO ₂	7.6		7.3	
HCO ₃ ⁻	37.9		38.0	
BE	12.6		12.4	
SaO ₂	91%		88%	
NIV	28/8 + 18 I-time 1.65 FiO ₂ 0.28		30/8 + 18 I-time 1.65 FiO ₂ 0.28	

	Repeat ABG	Changes made	Repeat ABG	Changes made	Repeat ABG
pH	7.31	IPAP ↑ 30	7.33	EPAP ↑ 10	7.41
PaCO ₂	10.2		9.8		7.5
PaO ₂	7.6		7.3		7.8
HCO ₃ ⁻	37.9		38.0		36.5
BE	12.6		12.4		12.0
SaO ₂	91%		88%		92%
NIV	28/8 + 18 I-time 1.65 FiO ₂ 0.28		30/8 + 18 I-time 1.65 FiO ₂ 0.28		30/10 + 18 I-time 1.65 FiO ₂ 0.28

Troubleshooting

- Obesity / OSA
- Increased PaCO₂
- Prolonged desaturation on NIV

OHS Settings

IPAP

Aim for 20-30 cmH₂O

EPAP

3 to 8cmH₂O

Back up rate

16 to 20

I-time

Set to achieve I:E ratio of 1:1

NMD settings

NMD settings	
IPAP	Start 10 cmH ₂ O (range 10-20 cmH ₂ O)
EPAP	3 cmH ₂ O
Back up rate	16 to 20
I-time	Set to achieve I:E ratio of 1:1

Troubleshooting Interfaces



Troubleshooting Interfaces



Troubleshooting Interfaces



Troubleshooting Interfaces



Troubleshooting Interfaces



Troubleshooting summary

- Recognise the need for NIV
- Treat underlying medical conditions
- Titrate settings for condition
- Monitor response to NIV
- Increased PaCO₂
- Target SpO₂ 88-92%
- Range of interfaces
- Airway clearance
- Wean after 24 hours of NIV and ABG's corrected

Troubleshooting summary

- Recognise the need for NIV
- Treat underlying medical conditions
- Titrate settings for condition
- Monitor response to NIV
- Increased PaCO₂
- Target SpO₂ 88-92%
- Range of interfaces
- Airway clearance
- Wean after 24 hours of NIV and ABG's corrected

Failure of 'NI' / 'V'

- *Failure of 'non-invasive'*
 - Agitation, low GCS, significant claustrophobia/panic
 - Transition to invasive ventilation early can be beneficial
 - (challenge prognostic pessimism)
- *Failure of 'ventilation' (despite good quality NIV)*
 - Ensure that efforts are made to optimise ventilation
 - Mask size/fit, leak, adequate pressures, I:E ratio, oxygenation, amount of time using ventilator, medical therapy correct
 - Failure of underlying lung despite best efforts to treat
 - Reality of treating severe lung disease

British Thoracic Society Quality Standards for acute non-invasive ventilation in adults

Michael Davies,¹ Martin Allen,² Andrew Bentley,³ Stephen C Bourke,⁴ Ben Creagh-Brown,^{5,6} Rachel D'Oliveiro,⁷ Alastair Glossop,⁸ Alasdair Gray,⁹ Phillip Jacobs,¹⁰ Ravi Mahadeva,¹¹ Rachael Moses,¹² Ian Setchfield¹³

To cite: Davies M, Allen M, Bentley A, *et al*. British Thoracic Society Quality Standards for acute non-invasive ventilation in adults. *BMJ Open Res Res* 2018;**5**:e000283. doi:10.1136/bmjresp-2018-000283

Received 6 February 2018
Accepted 7 February 2018

ABSTRACT

Introduction The purpose of the quality standards document is to provide healthcare professionals, commissioners, service providers and patients with a guide to standards of care that should be met for the provision of acute non-invasive ventilation in adults together with measurable markers of good practice.

Methods Development of British Thoracic Society (BTS) Quality Standards follows the BTS process of quality standard production based on the National Institute

- ▶ act as markers of high-quality, cost-effective patient care across a pathway or clinical area, covering treatment or prevention
 - ▶ are derived from the best available evidence.
- NICE Quality Standards and the NICE Quality Standards Process Guide² were used as a model for the development of BTS Quality Standards.
- The rationale for these quality standards

Specialist emergency care and COPD outcomes

Nicholas David Lane,^{1,2} Karen Brewin,¹ Tom Murray Hartley,^{1,2} William Keith Gray,¹ Mark Burgess,¹ John Steer,^{1,2} Stephen C Bourke^{1,2}

To cite: Lane ND, Brewin K, Hartley TM, *et al*. Specialist emergency care and COPD outcomes. *BMJ Open Resp Res* 2018;**5**:e000334. doi:10.1136/bmjresp-2018-000334

► Additional material is published online only. To view please visit the journal online (<http://dx.doi.org/10.1136/bmjresp-2018-000334>).

Received 28 June 2018
Revised 10 August 2018

ABSTRACT

Introduction In exacerbation of chronic obstructive pulmonary disease (ECOPD) requiring hospitalisation greater access to respiratory specialists improves outcome, but is not consistently delivered. The UK National Confidential Enquiry into Patient Outcome and Death 2015 enquiry showed over 25% of patients receiving acute non-invasive ventilation (NIV) for ECOPD died in hospital. On 16 June 2015 the Northumbria Specialist Emergency Care Hospital (NSECH) opened, introducing 24/7 specialty consultant on-call, direct admission from the emergency department to specialty wards and 7-day consultant review. A Respiratory Support Unit opened for patients requiring NIV. Before NSECH the NIV service

Key messages

- Does 7-day specialist emergency care improve outcomes in chronic obstructive pulmonary disease exacerbations requiring hospitalisation?
- In both ventilated and non-ventilated patients, this model of care was associated with reduced mortality and length of stay; but a small increase in 90-day readmission rates.
- The potential implications of wider adoption of this model of care to both patients and healthcare providers are substantial.

References

Davidson AC, Banham S, Elliott M *et al.* *Thorax* 2016;**71**:ii1-1135.

Davies M, Allen M, Bentley A, *et al.* British Thoracic Society Quality Standards for acute non-invasive ventilation in adults. *BMJ Open Resp Res* 2018;**5**:e000283.doi:10.1136/bmjresp-2018-000283

Carlos Echevarria, John Steer, Tom Hartley, Nicholas Lane & Stephen C. Bourke (2020) Predictors of NIV Treatment in Patients with COPD Exacerbation Complicated by Respiratory Acidaemia, *COPD: Journal of Chronic Obstructive Pulmonary Disease*, 17:5, 492-498, DOI: [10.1080/15412555.2020.1823358](https://doi.org/10.1080/15412555.2020.1823358)

NCEPOD inspiring change 2017 - <https://www.ncepod.org.uk/2017niv.html>

Plant PK, Owen JL, Elliott MW. Early use of non-invasive ventilation for acute exacerbations of chronic obstructive pulmonary disease on general respiratory wards: a multicentre randomised controlled trial. *Lancet*. 2000 Jun 3;355(9219):1931-5. doi: 10.1016/s0140-6736(00)02323-0. PMID: 10859037.

Wildman MJ, Sanderson C, Groves J, Reeves BC, Ayres J, Harrison D, Young D, Rowan K. Implications of prognostic pessimism in patients with chronic obstructive pulmonary disease (COPD) or asthma admitted to intensive care in the UK within the COPD and asthma outcome study (CAOS): multicentre observational cohort study. *BMJ*. 2007 Dec 1;335(7630):1132. doi: 10.1136/bmj.39371.524271.55. Epub 2007 Nov 1. PMID: 17975254; PMCID: PMC2099544.

Tom Hartley, Nicholas D. Lane, John Steer, Mark W. Elliott, Milind P. Sovani, Helen Jane Curtis, Elizabeth R. Fuller, Patrick B. Murphy, Dinesh Shrikrishna, Keir E. Lewis, Neil R. Ward, Chris D. Turnbull, Nicholas Hart, Stephen C. Bourke. *European Respiratory Journal* 2021 58: 2004042; DOI: 10.1183/13993003.04042-2020

Lane ND, Brewin K, Hartley TM, *et al.* Specialist emergency care and COPD outcomes. *BMJ Open Resp Res* 2018;**5**:e000334. doi:10.1136/bmjresp-2018-000334